"Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL"

Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults

68Ga-DOTA-peptides uptake (Maximum Standardized Uptake Value) in up to 5 liver metastases on PET-scan obtained after intra-hepatic injection

Safety profile : safety of 177Lu-DOTA-peptide after intra-arterial hepatic administration, 68Ga-DOTA-peptide uptake (SUVmax) on dose limiting organs (kidney, spleen, healthy liver, bone marrow) after 68Ga-DOTA-peptides by arterial intrahepatic and intravenous injections, 68Ga-DOTA-peptide uptake (SUVmax) on extra-hepatic lesion (if present) after 68Ga-DOTA-peptides by arterial intrahepatic and intravenous injections, Estimate the lesional and organ (kidney, spleen, healthy liver, bone marrow) absorbed doses after 177Lu-DOTA-peptide administration by intra-arterial hepatic and intravenous injections, Efficacy evaluation of the fifth cycle of 177Lu-DOTA-peptide therapy administered by intra-arterial hepatic infusion according to RECIST1.1 criteria

No related papers found yet.

France